LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), a global leader in bio-analytical testing, announces that it has successfully closed the transaction to acquire Eichrom Laboratoires (“Eichrom”), a key player in radioactivity and asbestos testing.
Eichrom is a sister Company of the well-known Eichrom Technologies, the first company to develop and commercialise extraction chromatographic resins, an essential reagent for identifying and quantifying radioactive elements precisely and quickly. Eichrom Technologies resins are used worldwide by all radioactivity testing laboratories.
Eichrom has long-standing relationships with all nuclear industry stakeholders and major players in France. Its comprehensive portfolio of analytical testing services enables the monitoring of drinking water and food, of the environmental surroundings of nuclear power plants and the decommissioning of nuclear sites. Eichrom performs radioactivity, chemical and asbestos analyses on radioactive or potentially-radioactive samples, providing a "one-stop testing shop" to players in the nuclear industry. The company is located near Rennes in the west of France. Eichrom is ISO 17025 accredited by the Comité français d'accréditation (COFRAC), a member of the globally-recognized International Laboratory Accreditation Cooperation (ILAC). It employs 57 staff and generated revenues close to EUR 4m in 2017.
The acquisition of Eichrom expands Eurofins’ portfolio of analytical testing services, which will now offer a comprehensive suite of state-of-the-art testing services to a broad range of customers involved in the nuclear industry.
Comment from Dr. Gilles Martin, Eurofins CEO: “We are pleased to welcome Eichrom, an entrepreneurial company, to Eurofins’ family of businesses. With this acquisition, in addition to its activities in this field in Japan, the USA and the Nordic countries, Eurofins becomes a key player in radioactivity testing and offers its clients a broad and comprehensive testing portfolio. We look forward to strengthening Eichrom portfolio and operating footprint by providing them access to the full range of services and capabilities of the Eurofins Group as well as access to the Group’s clients.”
For more information, please visit www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 35,000 staff in more than 400 laboratories across 44 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.